NSE / BSEHealthcare
β‚Ή182.20-4.15-2.23%
P/E0.0Mkt Capβ‚Ή4.13 K CrEV/EBITDA67.5

Dishman Carbogen Amcis Limited

P/E0.0Mkt Capβ‚Ή4.13 K CrEV/EBITDA67.5
Company Profile

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
β€”
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 23.77% over 1Y
Monthly Returns

Historically, Nov has averaged the highest return (+7.7%); May the lowest (-5.9%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-12.0%Negative MonthJan 2026: -11.98%-19.8%Negative MonthFeb 2026: -19.78%-25.7%Negative MonthMar 2026: -25.74%+41.2%Positive MonthApr 2026: +41.23%+6.0%Positive MonthMay 2026: +6.02%-10.0%Negative MonthJun 2026: -9.97%+4.0%*Positive MonthJul 2026: +3.97%β€”β€”β€”β€”β€”
2025-14.0%Negative MonthJan 2025: -13.97%-14.3%Negative MonthFeb 2025: -14.26%+9.2%Positive MonthMar 2025: +9.18%-11.4%Negative MonthApr 2025: -11.42%+38.0%Positive MonthMay 2025: +38.03%-5.5%Negative MonthJun 2025: -5.45%+0.2%Neutral MonthJul 2025: +0.16%+4.7%Positive MonthAug 2025: +4.74%+4.8%Positive MonthSep 2025: +4.76%+5.5%Positive MonthOct 2025: +5.53%-17.9%Negative MonthNov 2025: -17.91%+3.5%Positive MonthDec 2025: +3.51%
2024+13.8%Positive MonthJan 2024: +13.82%+30.9%Positive MonthFeb 2024: +30.94%-7.4%Negative MonthMar 2024: -7.44%-1.4%Neutral MonthApr 2024: -1.40%-30.7%Negative MonthMay 2024: -30.74%+11.5%Positive MonthJun 2024: +11.53%+12.8%Positive MonthJul 2024: +12.76%+0.4%Neutral MonthAug 2024: +0.42%-11.4%Negative MonthSep 2024: -11.42%+8.4%Positive MonthOct 2024: +8.36%+25.2%Positive MonthNov 2024: +25.25%+10.6%Positive MonthDec 2024: +10.60%
2023-10.8%Negative MonthJan 2023: -10.78%+38.3%Positive MonthFeb 2023: +38.33%+6.3%Positive MonthMar 2023: +6.31%+10.9%Positive MonthApr 2023: +10.95%-14.6%Negative MonthMay 2023: -14.64%+19.1%Positive MonthJun 2023: +19.09%+13.0%Positive MonthJul 2023: +12.98%-1.6%Neutral MonthAug 2023: -1.64%+3.4%Positive MonthSep 2023: +3.36%-12.2%Negative MonthOct 2023: -12.19%+14.9%Positive MonthNov 2023: +14.95%+4.8%Positive MonthDec 2023: +4.75%
2022-3.1%Negative MonthJan 2022: -3.12%-15.0%Negative MonthFeb 2022: -15.05%+11.4%Positive MonthMar 2022: +11.37%-10.9%Negative MonthApr 2022: -10.86%-28.1%Negative MonthMay 2022: -28.11%-4.5%Negative MonthJun 2022: -4.47%+11.6%Positive MonthJul 2022: +11.60%-6.7%Negative MonthAug 2022: -6.72%-18.1%Negative MonthSep 2022: -18.05%+2.1%Positive MonthOct 2022: +2.12%+0.2%Neutral MonthNov 2022: +0.20%-3.9%Negative MonthDec 2022: -3.94%
2021β€”β€”β€”β€”β€”+2.9%Positive MonthJun 2021: +2.93%-2.5%Negative MonthJul 2021: -2.49%-11.2%Negative MonthAug 2021: -11.23%+7.8%Positive MonthSep 2021: +7.78%+2.3%Positive MonthOct 2021: +2.27%+15.9%Positive MonthNov 2021: +15.90%-14.9%Negative MonthDec 2021: -14.86%
AvgΒ±SD-5.2%Β±10.2%+4.0%Β±25.2%-1.3%Β±13.9%+5.7%Β±19.5%-5.9%Β±25.5%+2.3%Β±10.2%+6.5%Β±6.3%-2.9%Β±5.6%-2.7%Β±10.1%+1.2%Β±7.1%+7.7%Β±15.1%+0.0%Β±8.8%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.735x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή400.00 Crβ–² 22.3%
EBITDA Growthβ€”
Net Profitβ‚Ή-10.00β–Ό 86.8%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 740.0%
Revenue CAGR 5Y-10.9%
EBITDA CAGR 5Y-22.7%
Net Profit CAGR 5Y0.0%
NP Growth 1Y-86.8%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή400.00 Crβ€”β‚Ή-10.00β€”β€”-0.2%22.3%-86.8%
Mar 2024β‚Ή327.00 Crβ€”β‚Ή-76.00β€”β€”-1.9%-18.9%28.8%
Mar 2023β‚Ή403.00 Crβ€”β‚Ή-59.00β€”β€”-1.4%31.3%84.4%
Mar 2022β‚Ή307.00 Crβ€”β‚Ή-32.00β€”β€”-0.8%53.5%-86.3%
Mar 2021β‚Ή200.00 Crβ€”β‚Ή-233.00β€”β€”-5.0%-65.6%-697.4%
Mar 2020β‚Ή581.00 Crβ€”β‚Ή39.00 Crβ€”β€”0.8%5.8%-30.4%
Mar 2019β‚Ή549.00 Crβ€”β‚Ή56.00 Crβ€”β€”1.1%15.8%51.4%
Mar 2018β‚Ή474.00 Crβ€”β‚Ή37.00 Crβ€”β€”0.8%5.1%54.2%
Mar 2017β‚Ή451.00 Crβ€”β‚Ή24.00 Crβ€”β€”0.5%6342.9%2300.0%
Mar 2016β‚Ή7.00 Crβ€”β‚Ή1.00 Crβ€”β€”2000.0%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales07451474549581200307403327400326
Total Expenses05303308356401253267394321328275
EBIT / Operating Profit02148166194179-5340977251
OPM %-25%33%35%35%31%-26%13%2%2%18%16%
Other Income0071667264595349603346
Finance Costs1139354747343758687080
Depreciation & Amortisation00136134136141141140961026565
Profit Before Tax0144628255-169-84-96-103-31-47
Tax %0%12%45%40%31%31%38%-63%-39%-26%-68%-
Net Profit / PAT0124375639-233-32-59-76-10-32
EPS (β‚Ή)---2.303.472.46-14.85-2.01-3.75-4.87-0.63-2.02
Dividend Payout %0%0%0%0%6%0%0%0%0%0%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Dishman Carbogen Amcis Limitedthis co.β‚Ή4.13 K Crβ‚Ή400.00 Cr0.001.0467.4722.3%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Dishman Carbogen Amcis Limited and the metrics that matter.

Browse the full Equiscale Academy